Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Benitec Biopharma

DB:BJ9
Snowflake Description

Flawless balance sheet and overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
BJ9
DB
A$8M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Benitec Biopharma Limited, a biotechnology company, develops treatments for chronic and life-threatening human diseases based on its gene silencing therapy, DNA-directed RNA interference (ddRNAi) in Australia and the United States. The last earnings update was 39 days ago. More info.


Add to Portfolio Compare Print
  • Benitec Biopharma has significant price volatility in the past 3 months.
BJ9 Share Price and Events
7 Day Returns
0%
DB:BJ9
-0.7%
DE Biotechs
-0.6%
DE Market
1 Year Returns
-84.7%
DB:BJ9
-13.2%
DE Biotechs
-20.9%
DE Market
BJ9 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Benitec Biopharma (BJ9) 0% -34.3% -32.4% -84.7% -92.6% -98.1%
DE Biotechs -0.7% -8.2% -21% -13.2% 13.2% -11.8%
DE Market -0.6% -18.6% -26.2% -20.9% -25.8% -31.8%
1 Year Return vs Industry and Market
  • BJ9 underperformed the Biotechs industry which returned -13.2% over the past year.
  • BJ9 underperformed the Market in Germany which returned -20.9% over the past year.
Price Volatility
BJ9
Industry
5yr Volatility vs Market

Value

 Is Benitec Biopharma undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Benitec Biopharma. This is due to cash flow or dividend data being unavailable. The share price is €0.0115.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Benitec Biopharma's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Benitec Biopharma's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:BJ9 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in AUD A$-0.04
ASX:BLT Share Price ** ASX (2020-03-27) in AUD A$0.03
Europe Biotechs Industry PE Ratio Median Figure of 24 Publicly-Listed Biotechs Companies 40.67x
Germany Market PE Ratio Median Figure of 401 Publicly-Listed Companies 16.57x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Benitec Biopharma.

DB:BJ9 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= ASX:BLT Share Price ÷ EPS (both in AUD)

= 0.03 ÷ -0.04

-0.73x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Benitec Biopharma is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Benitec Biopharma is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Benitec Biopharma's expected growth come at a high price?
Raw Data
DB:BJ9 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -0.73x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Europe Biotechs Industry PEG Ratio Median Figure of 19 Publicly-Listed Biotechs Companies 1.62x
Germany Market PEG Ratio Median Figure of 256 Publicly-Listed Companies 1.17x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Benitec Biopharma, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Benitec Biopharma's assets?
Raw Data
DB:BJ9 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in AUD A$0.07
ASX:BLT Share Price * ASX (2020-03-27) in AUD A$0.03
Germany Biotechs Industry PB Ratio Median Figure of 14 Publicly-Listed Biotechs Companies 3.33x
Germany Market PB Ratio Median Figure of 572 Publicly-Listed Companies 1.44x
DB:BJ9 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= ASX:BLT Share Price ÷ Book Value per Share (both in AUD)

= 0.03 ÷ 0.07

0.38x

* Primary Listing of Benitec Biopharma.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Benitec Biopharma is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Benitec Biopharma's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Benitec Biopharma has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Benitec Biopharma expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Benitec Biopharma has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
55.2%
Expected Biotechs industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Benitec Biopharma expected to grow at an attractive rate?
  • Unable to compare Benitec Biopharma's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Benitec Biopharma's earnings growth to the Germany market average as no estimate data is available.
  • Unable to compare Benitec Biopharma's revenue growth to the Germany market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
DB:BJ9 Future Growth Rates Data Sources
Data Point Source Value (per year)
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 55.2%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 24%
Germany Market Earnings Growth Rate Market Cap Weighted Average 14.1%
Germany Market Revenue Growth Rate Market Cap Weighted Average 3.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:BJ9 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in AUD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:BJ9 Past Financials Data
Date (Data in AUD Millions) Revenue Cash Flow Net Income *
2019-12-31 2 -6 -10
2019-09-30 10 0 -3
2019-06-30 17 6 4
2019-03-31 17 3 4
2018-12-31 17 3 3
2018-09-30 11 -4 -4
2018-06-30 4 -10 -12
2018-03-31 5 -9 -11
2017-12-31 7 -7 -9
2017-09-30 6 -6 -9
2017-06-30 11 -8 -6
2017-03-31 10 -8 -9

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Benitec Biopharma is high growth as no earnings estimate data is available.
  • Unable to determine if Benitec Biopharma is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:BJ9 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Benitec Biopharma Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:BJ9 Past Financials Data
Date (Data in AUD Millions) EPS *
2019-12-31 -0.04
2019-09-30 -0.01
2019-06-30 0.02
2019-03-31 0.01
2018-12-31 0.01
2018-09-30 -0.02
2018-06-30 -0.06
2018-03-31 -0.05
2017-12-31 -0.04
2017-09-30 -0.05
2017-06-30 -0.03
2017-03-31 -0.06

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Benitec Biopharma will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Examine Benitec Biopharma's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  2. Benitec Biopharma's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  3. Benitec Biopharma's competitive advantages and company strategy can generally be found in its financial reports archived here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Benitec Biopharma's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Benitec Biopharma has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Benitec Biopharma performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Benitec Biopharma's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Benitec Biopharma does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.
  • Unable to compare Benitec Biopharma's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Benitec Biopharma's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Benitec Biopharma's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Benitec Biopharma Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:BJ9 Past Revenue, Cash Flow and Net Income Data
Date (Data in AUD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 1.96 -9.68 9.67 1.52
2019-09-30 9.51 -2.79 9.59 2.31
2019-06-30 17.07 4.09 9.51 3.10
2019-03-31 17.03 3.54 9.41 4.40
2018-12-31 17.40 3.23 9.28 5.25
2018-09-30 11.13 -4.23 8.96 6.31
2018-06-30 4.38 -11.64 8.73 6.89
2018-03-31 4.82 -11.18 8.64 6.50
2017-12-31 7.42 -8.54 8.66 6.22
2017-09-30 6.19 -9.31 9.10 5.81
2017-06-30 11.09 -5.69 9.10 6.93
2017-03-31 9.82 -9.37 9.14 7.48
2016-12-31 9.66 -11.67 9.51 9.14
2016-09-30 9.61 -15.34 11.20 9.74
2016-06-30 4.05 -24.78 11.71 13.29
2016-03-31 4.42 -23.76 12.08 13.15
2015-12-31 3.08 -22.54 11.26 12.17
2015-09-30 3.31 -17.68 8.93 11.19
2015-06-30 3.40 -11.51 8.14 6.23
2015-03-31 3.54 -8.12 6.89 5.13
2014-12-31 1.79 -8.72 6.43 4.12
2014-09-30 1.58 -7.88 5.62 3.94
2014-06-30 1.37 -7.04 4.81 3.76
2014-03-31 1.23 -5.16 4.39 3.04
2013-12-31 1.09 -3.29 3.97 2.32
2013-09-30 1.28 -3.39 3.78 1.80
2013-06-30 1.46 -3.49 3.59 1.28

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Benitec Biopharma has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Benitec Biopharma has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Benitec Biopharma improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Benitec Biopharma's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Benitec Biopharma has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Benitec Biopharma's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Benitec Biopharma's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Benitec Biopharma is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Benitec Biopharma's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Benitec Biopharma's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Benitec Biopharma has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Benitec Biopharma Company Filings, last reported 3 months ago.

DB:BJ9 Past Debt and Equity Data
Date (Data in AUD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 21.74 0.00 19.66
2019-09-30 21.74 0.00 19.66
2019-06-30 23.66 0.00 22.41
2019-03-31 23.66 0.00 22.41
2018-12-31 28.11 0.00 23.19
2018-09-30 28.11 0.00 23.19
2018-06-30 18.74 0.00 16.12
2018-03-31 13.20 0.00 10.58
2017-12-31 15.93 0.00 10.34
2017-09-30 18.78 0.00 14.80
2017-06-30 21.51 0.00 17.38
2017-03-31 23.98 0.00 19.72
2016-12-31 18.55 0.00 12.37
2016-09-30 19.74 0.00 13.39
2016-06-30 18.84 0.00 18.26
2016-03-31 24.84 0.00 19.88
2015-12-31 27.29 0.00 24.76
2015-09-30 23.88 0.00 21.79
2015-06-30 23.88 0.00 21.79
2015-03-31
2014-12-31 29.62 0.00 26.83
2014-09-30 29.62 0.00 26.83
2014-06-30 33.54 0.00 31.36
2014-03-31 33.54 0.00 31.36
2013-12-31 7.69 0.00 5.18
2013-09-30 7.69 0.00 5.18
2013-06-30 0.64 0.00 1.59
  • Benitec Biopharma has no debt.
  • Benitec Biopharma has not taken on any debt in the past 5 years.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Benitec Biopharma has sufficient cash runway for more than 3 years based on current free cash flow.
  • Benitec Biopharma has sufficient cash runway for 1.3 years if free cash flow continues to reduce at historical rates of -19.9% each year.
X
Financial health checks
We assess Benitec Biopharma's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Benitec Biopharma has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Benitec Biopharma's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Benitec Biopharma dividends.
If you bought €2,000 of Benitec Biopharma shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Benitec Biopharma's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Benitec Biopharma's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:BJ9 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 1.1%
Germany Market Average Dividend Yield Market Cap Weighted Average of 316 Stocks 3.9%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.9%
Germany Bottom 25% Dividend Yield 25th Percentile 1.7%
Germany Top 25% Dividend Yield 75th Percentile 4.9%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Benitec Biopharma has not reported any payouts.
  • Unable to verify if Benitec Biopharma's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Benitec Biopharma's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Benitec Biopharma has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Benitec Biopharma's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.9%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Benitec Biopharma afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Benitec Biopharma has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Benitec Biopharma's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Jerel Banks
COMPENSATION A$1,293,248
TENURE AS CEO 1.8 years
CEO Bio

Dr. Jerel A. Banks, Ph.D., M.D. has been Chief Executive Officer of Benitec Biopharma Limited since June 26, 2018. Dr. Banks serves as Chief Investment Officer of NantVentures. Dr. Banks has been Senior Vice President of Mergers and Acquisitions at NantKwest, Inc. since September 22, 2015. Dr. Banks serves as a Vice President, Portfolio Manager and Research Analyst at Franklin Advisers, Inc. Dr. Banks serves as Vice President, Portfolio Manager and Research Analyst at Franklin Templeton Investments. Dr. Banks served as Portfolio Manager and Research Analyst at Franklin Templeton Investment Funds SICAV - Franklin Biotechnology Discovery Fund and Franklin Strategic Series - Franklin Biotechnology Discovery Fund. Dr. Banks joined Franklin Templeton Investments in 2012. Previously, Dr. Banks served as a Senior Equity Research Analyst covering the biotechnology sector and Financial Analyst at Sectoral Asset Management Inc., and Apothecary Capital. Dr. Banks served as an Equity Research Associate on the healthcare investment team at Capital Research and Management. Dr. Banks serves as the Executive Chairman of the Board at Benitec Biopharma Limited since June 15, 2018 and served as its Chairman of the Board from October 12, 2017 to June 15, 2018. Dr. Banks served as a Non-Executive Director of Benitec Biopharma Limited from October 26, 2016 to June 15, 2018. Dr. Banks received an M.D. and Ph.D. in Organic Chemistry from Brown University and holds a B.A. in Chemistry from Princeton University.

CEO Compensation
  • Jerel's compensation has increased whilst company is loss making.
  • Jerel's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure of the Benitec Biopharma management team in years:

2.8
Average Tenure
  • The tenure for the Benitec Biopharma management team is about average.
Management Team

Jerel Banks

TITLE
CEO & Executive Chairman
COMPENSATION
A$1M
TENURE
1.8 yrs

Megan Boston

TITLE
Executive Director
COMPENSATION
A$394K
TENURE
1.8 yrs

Bryan Dulhunty

TITLE
Chief Financial Officer
TENURE
3.7 yrs

Michael Graham

TITLE
Head of Discovery & Founding Scientist
COMPENSATION
A$217K
TENURE
4.8 yrs

Craig Lewis

TITLE
Chief Medical Adviser
TENURE
6.1 yrs

Claudia Kloth

TITLE
Senior Vice President of Manufacturing

Oliver Kidd

TITLE
Company Secretary
TENURE
1.8 yrs
Board of Directors Tenure

Average tenure of the Benitec Biopharma board of directors in years:

4.5
Average Tenure
  • The tenure for the Benitec Biopharma board of directors is about average.
Board of Directors

Megan Boston

TITLE
Executive Director
COMPENSATION
A$394K
TENURE
3.7 yrs

Peter Francis

TITLE
Non-Executive Director
COMPENSATION
A$77K
AGE
63
TENURE
14.2 yrs

Jerel Banks

TITLE
CEO & Executive Chairman
COMPENSATION
A$1M
TENURE
1.8 yrs

J. Buchi

TITLE
Non-Executive Director
COMPENSATION
A$77K
TENURE
7 yrs

Geoff McCaughan

TITLE
Member of Hepatology Clinical Advisory Board
TENURE
4.5 yrs

Harry Janssen

TITLE
Member of Hepatology Clinical Advisory Board
TENURE
4.5 yrs

Keyur Patel

TITLE
Member of Hepatology Clinical Advisory Board
TENURE
4.5 yrs

George Dickson

TITLE
Member of Scientific & Clinical Advisory Board
Who owns this company?
Recent Insider Trading
  • More shares have been bought than sold by Benitec Biopharma individual insiders in the past 3 months, but not in substantial volumes.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
29. Mar 20 Buy Peter Francis Individual 27. Mar 20 27. Mar 20 875,000 €0.02 €15,022
X
Management checks
We assess Benitec Biopharma's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Benitec Biopharma has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Benitec Biopharma Limited, a biotechnology company, develops treatments for chronic and life-threatening human diseases based on its gene silencing therapy, DNA-directed RNA interference (ddRNAi) in Australia and the United States. The company provides BB-301, a single administration ddRNAi-based gene therapy for the treatment of oculopharyngeal muscular dystrophy; and BB-103 ddRNAi-based therapies for the treatment of human hepatitis B. The company was founded in 1995 and is headquartered in Melbourne, Australia.

Details
Name: Benitec Biopharma Limited
BJ9
Exchange: DB
Founded: 1995
A$4,652,860
321,287,046
Website: http://www.benitec.com
Address: Benitec Biopharma Limited
114 William Street,
Level 14,
Melbourne,
Victoria, 3000,
Australia
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
ASX BLT Ordinary Shares Australian Securities Exchange AU AUD 04. May 2002
OTCPK BNIK.F Ordinary Shares Pink Sheets LLC US USD 04. May 2002
DB BJ9 Ordinary Shares Deutsche Boerse AG DE EUR 04. May 2002
BRSE BJ9 Ordinary Shares Berne Stock Exchange CH CHF 04. May 2002
CHIA BLT Ordinary Shares Chi-X Australia AU AUD 04. May 2002
NasdaqCM BNTC SPON ADR EA REPR 20 ORD Nasdaq Capital Market US USD 13. Jul 2012
DB BJ93 NPV Deutsche Boerse AG DE EUR 10. Feb 2020
DB BJ92 SPON ADR EA REPR 20 ORD Deutsche Boerse AG DE EUR 13. Jul 2012
Number of employees
Current staff
Staff numbers
0
Benitec Biopharma employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/05 21:05
End of day share price update: 2020/03/27 00:00
Last earnings filing: 2020/02/26
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/06/30


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.